Evaluation of the EarEEG System for Detection of Hypoglycaemia-induced Changes in the EEG in Subjects With Type 1 Diabetes

NCT03022058 | Completed DMC

• 1 other identifier: 56205
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The EarEEG system is a novel non-invasive, unobstructed and discrete method for recording EEG in which the signal is recorded using dry-contact electrodes embedded on a customised ear piece. One intended medical indication of the EarEEG system is the detection of hypoglycaemia-induced changes in the EEG in patients with type 1 diabetes. Currently, no studies exist investigating the detection of hypoglycaemic episodes by use of ear electrodes. While a finger prick test accurately measures the blood glucose level, it does not provide continuous measurements, and hence it is unreliable as a hypoglycaemia alarm. Recent studies have indicated that the use of continuous glucose monitoring (CGM) reduces the risk of severe hypoglycaemia. However, some find these devices troublesome to use and utilisation of CGM has remained limited to date. Observational data show that only a small percentage of patients with type 1 diabetes are using CGM on an ongoing basis. Thus, there is a medical need for a reliable hypoglycaemia detection device which is easy and convenient to use. This clinical study aims at investigating the feasibility of measuring hypoglycaemia induced changes in the EEG by use of the EarEEG system.

Conditions

Diabetes Mellitus, Type 1

Outcome Measures

Primary Outcomes (1)

• Presence of significant qEEG hypoglycaemia indicators when comparing normo- and hypoglycaemic EEG as measured by the EarEEG systems for subjects where hypoglycaemia-induced changes have been observed in the scalp EEG (visit 4)

  During insulin-induced hypoglycaemia

  Up to 8 hours

Study Arms (1)

Patients with type 1 diabetes mellitus

EXPERIMENTAL

Device: Ear-EEG system

Interventions

Ear-EEG system DEVICE

Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.

Patients with type 1 diabetes mellitus

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Informed consent obtained before any study related activities1
• Age 18-70 years
• Patients with type 1 diabetes (duration ≥ 5 years)

You may not qualify if:

• Severe cardiac disease
• History of myocardial infarction
• Cardiac arrhythmia
• Previous stroke or cerebral haemorrhage and any other structural cerebral disease
• Uraemia defined as s-creatinine ≥ 3 times upper reference value,
• Liver disease defined as s-ALAT ≥ 3 times upper reference interval
• Epilepsy
• Use of antiepileptic drugs for any purposes
• Use of the following drugs: Chemotherapeutic drugs of any kind, methotrexate, third generation antipsychotic drugs (aripiprazole, quetiapine, clozapine, ziprasidone, paliperidone, risperidone, sertindole, amisulpride, olanzapine)
• Known or suspected abuse of alcohol defined as estimated consumption beyond that, which is recommended by the DHA1 or any other neuro-active substances
• Use of hearing aid or cochlear implants2
• Allergic contact dermatitis caused by metals or generally prone to skin irritation
• Narrow or malformed ear canals
• Patients that are judged incapable of understanding the patient information or who are not capable of carrying through the investigation
• Pregnancy

Sponsors & Collaborators

• Odense University Hospital: lead
• University of Aarhus: collaborator
• T&W Engineering A/S: collaborator
• UNEEG Medical A/S: collaborator

Study Sites (1)

Diabetes Research Center

Odense, 5000, Denmark

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Henning Beck-Nielsen, DMSc

  Odense University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: December 13, 2016
• First Posted: January 16, 2017
• Study Start: June 22, 2017
• Primary Completion: November 16, 2017
• Study Completion: November 16, 2017
• Last Updated: April 11, 2018

Record last verified: 2018-04

Locations

DK (1)